Compass Therapeutics' headline analyst upside rests on a price target the engine itself rejected as implausible, and while the stock shows an overbought bounce off a death cross, deep quality problems, cash burn, and elevated short interest keep conviction and position sizing at essentially zero.
Thesis pillars
- Rejected Analyst Target Caps Upside→Stable
- Death Cross Recovery As Overbought Bounce→Stable
- Quality Deficit From Cash Burn→Stable
- +2 more pillars — see the Why tab for full reasoning
Compass Therapeutics, Inc. (CMPX) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $2.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 22%; Elevated put/call ratio: 2.00; Below-average business quality.
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing four antibody-based product candidates targeting angiogenesis and immune checkpoint pathways. Its lead candidate, tovecimig, licensed exclusively (outside South Korea) from ABL Bio, met the... Read more
Sell if holding. Engine safety override at $2.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 22%; Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 70. Score 4.3/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 39d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Compass Therapeutics, Inc.
About Compass Therapeutics, Inc.
Compass Therapeutics' lead product candidate, tovecimig, met the primary endpoint of its randomized Phase 2/3 trial in biliary tract cancer (BTC), showing a 17.1% overall response rate combined with paclitaxel versus 5.3% for paclitaxel alone (p=0.031), with overall survival data expected in April 2026. The company has an accumulated deficit of $431 million as of December 31, 2025, has generated no product revenue since its 2014 founding, and has funded operations through private placements, a public offering, a PIPE and an at-the-market program.
Compass's pipeline spans four clinical-stage antibodies targeting angiogenesis and immune-checkpoint pathways: tovecimig (DLL4 x VEGF-A) in BTC and, following a 5% ORR in a Phase 2 colorectal cancer monotherapy study, additional solid-tumor indications; CTX-471, a CD137 agonist showing monotherapy activity in melanoma, small cell lung cancer and mesothelioma, heading into a Phase 2 basket study using the NCAM biomarker in mid-2026; CTX-8371, a PD-1 x PD-L1 bispecific in Phase 1 expansion cohorts for NSCLC, triple-negative breast cancer and Hodgkin lymphoma; and CTX-10726, a PD-1 x VEGF-A bispecific that entered Phase 1 dosing in early 2026. Compass licenses exclusive global rights to tovecimig outside South Korea from ABL Bio, while Handok Pharmaceuticals holds South Korean rights and Elpiscience holds China rights. BTC affects an estimated 26,500 newly diagnosed U.S. patients and over 200,000 patients worldwide each year, with no accepted standard of care in later treatment lines.
Show full overview
Compass's near-term outcome rests heavily on one licensed molecule: the 10-K identifies tovecimig as the company's lead product candidate, and its rights outside South Korea derive entirely from an exclusive license with ABL Bio, a South Korea-based clinical-stage company. A disruption to that license, or disappointing overall-survival data from the ongoing Phase 2/3 BTC trial due in April 2026, would remove Compass's most advanced commercial prospect, since its three earlier-stage candidates, CTX-471, CTX-8371 and CTX-10726, remain in Phase 1 or Phase 2 development and are years from potential approval.
See also: Healthcare · Biotechnology
From Compass Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinetovecimig (lead product candidate)10-K Item 1: 'Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4'
- HIGHcounterpartyABL Bio (tovecimig licensor)10-K Item 1: 'We have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc. (“ABL Bio”), a South Korea-based clinical-stage company focused on developing antibody therapeutics.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $2.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 22%; Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 70. Prior stop was $2.13. Score 4.3/10, moderate confidence.
Take-profit target: $2.25 (-1.7% upside). Prior stop was $2.13. Stop-loss: $2.13.
Concentration risk — Pipeline: tovecimig (lead product candidate); Concentration risk — Counterparty: ABL Bio (tovecimig licensor); DATA_ISSUE: analyst_target_implausible (raw $8.50 vs price $2.29 — ratio 3.7×). Rejected, falling back to technical TP..
Compass Therapeutics, Inc. trades at a P/E of N/A (forward -4.9). TrendMatrix value score: 5.0/10. Verdict: Sell.
20 analysts cover CMPX with a consensus score of 4.3/5. Average price target: $9.
What does Compass Therapeutics, Inc. do?Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing four antibody-based product...
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing four antibody-based product candidates targeting angiogenesis and immune checkpoint pathways. Its lead candidate, tovecimig, licensed exclusively (outside South Korea) from ABL Bio, met the primary endpoint of a Phase 2/3 trial in biliary tract cancer with a 17.1% overall response rate versus 5.3% for chemotherapy alone; the company has no approved products or product revenue and reported an accumulated deficit of $431 million as of December 31, 2025.